The role of SLAM/CD2 polymorphisms in systemic autoimmunity

Current Opinion in Immunology

Volumn 22, Issue 6, 2010, Pages 706-714

  Wang, Andrew ^a   Batteux, Frederic ^b   Wakeland, Edward K ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CYTOKINE; SIGNALING LYMPHOCYTE ACTIVATION MOLECULE ASSOCIATED PROTEIN; T LYMPHOCYTE RECEPTOR;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY REACTION; APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CD2 GENE; CD84 GENE; CELL CYCLE PROGRESSION; CELL INTERACTION; CLONAL ANERGY; CYTOKINE PRODUCTION; DNA POLYMORPHISM; GENE; GENE TARGETING; GENETIC SUSCEPTIBILITY; GENETIC TRAIT; GENETIC VARIABILITY; GERMINAL CENTER; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOREGULATION; IMMUNOSTIMULATION; INNATE IMMUNITY; LY108 GENE; LY9 GENE; LYMPHOCYTE FUNCTION; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTIGENE FAMILY; NATURAL KILLER CELL; NONHUMAN; REGULATOR GENE; REVIEW; SLAM GENE; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD2; ANTIGENS, LY; AUTOIMMUNITY; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; POLYMORPHISM, GENETIC;

EID: 78649845328     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2010.10.014     Document Type: Review

References (70)

1. Veillette A. Immune regulation by SLAM family receptors and SAP-related adaptors. Nat Rev Immunol 2006, 6:56-66.
2. Engel P., Eck M.J., Terhorst C. The SAP and SLAM families in immune responses and X-linked lymphoproliferative disease. Nat Rev Immunol 2003, 3:813-821.
3. Chan A.Y., Westcott J.M., Mooney J.M., Wakeland E.K., Schatzle J.D. The role of SAP and the SLAM family in autoimmunity. Curr Opin Immunol 2006, 18:656-664.
4. Kingsbury G.A., Feeney L.A., Nong Y., Calandra S.A., Murphy C.J., Corcoran J.M., Wang Y., Prabhu Das M.R., Busfield S.J., Fraser C.C., Villeval J.L. Cloning, expression, and function of BLAME, a novel member of the CD2 family. J Immunol 2001, 166:5675-5680.
5. Fraser C.C., Howie D., Morra M., Qiu Y., Murphy C., Shen Q., Gutierrez-Ramos J.C., Coyle A., Kingsbury G.A., Terhorst C. Identification and characterization of SF2000 and SF2001, two new members of the immune receptor SLAM/CD2 family. Immunogenetics 2002, 53:843-850.
6. Flajnik M.F., Kasahara M. Comparative genomics of the MHC: glimpses into the evolution of the adaptive immune system. Immunity 2001, 15:351-362.
7. Mikkola H.K., Orkin S.H. The journey of developing hematopoietic stem cells. Development 2006, 133:3733-3744.
8. Limaye N., Belobrajdic K.A., Wandstrat A.E., Bonhomme F., Edwards S.V., Wakeland E.K. Prevalence and evolutionary origins of autoimmune susceptibility alleles in natural mouse populations. Genes Immun 2007, 9:61-68.
9. Wandstrat A.E., Nguyen C., Limaye N., Chan A.Y., Subramanian S., Tian X.H., Yim Y.S., Pertsemlidis A., Garner H.R., Morel L., Wakeland E.K. Association of extensive polymorphisms in the SLAM/CD2 gene cluster with murine lupus. Immunity 2004, 21:769-780.
10. Aktan I., Chant A., Borg Z.D., Damby D.E., Leenstra P.C., Lilley G.W., Petty J., Suratt B.T., Teuscher C., Wakeland E.K., et al. Slam haplotypes modulate the response to lipopolysaccharide in vivo through control of NKT cell number and function. J Immunol 2010, 185:144-156.
11. Kumar K.R., Li L., Yan M., Bhaskarabhatla M., Mobley A.B., Nguyen C., Mooney J.M., Schatzle J.D., Wakeland E.K., Mohan C. Regulation of B cell tolerance by the lupus susceptibility gene Ly108. Science 2006, 312:1665-1669.
12. Morel L., Blenman K.R., Croker B.P., Wakeland E.K. The major murine systemic lupus erythematosus susceptibility locus, Sle1, is a cluster of functionally related genes. Proc Natl Acad Sci U S A 2001, 98:1787-1792.
13. Arbuckle M.R., McClain M.T., Rubertone M.V., Scofield R.H., Dennis G.J., James J.A., Harley J.B. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003, 349:1526-1533.
14. Jorgensen T.N., Alfaro J., Enriquez H.L., Jiang C., Loo W.M., Atencio S., Bupp M.R., Mailloux C.M., Metzger T., Flannery S., et al. Development of murine lupus involves the combined genetic contribution of the SLAM and FcgammaR intervals within the Nba2 autoimmune susceptibility locus. J Immunol 2010, 184:775-786.
15. Subramanian S., Wakeland E.K. The importance of epistatic interactions in the development of autoimmunity. Novartis Found Symp 2005, 267:76-88. (discussion 88-93).
16. Morel L., Tian X.H., Croker B.P., Wakeland E.K. Epistatic modifiers of autoimmunity in a murine model of lupus nephritis. Immunity 1999, 11:131-139.
17. Subramanian S., Tus K., Li Q.Z., Wang A., Tian X.H., Zhou J., Liang C., Bartov G., McDaniel L.D., Zhou X.J., et al. A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc Natl Acad Sci U S A 2006, 103:9970-9975.
18. Subramanian S., Yim Y.S., Liu K., Tus K., Zhou X.J., Wakeland E.K. Epistatic suppression of systemic lupus erythematosus: fine mapping of Sles1 to less than 1Mb. J Immunol 2005, 175:1062-1072.
19. Bolland S., Yim Y.S., Tus K., Wakeland E.K., Ravetch J.V. Genetic modifiers of systemic lupus erythematosus in FcgammaRIIB(-/-) mice. J Exp Med 2002, 195:1167-1174.
20. Bolland S., Ravetch J.V. Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity 2000, 13:277-285.
21. Cunninghame Graham D.S., Vyse T.J., Fortin P.R., Montpetit A., Cai Y.C., Lim S., McKenzie T., Farwell L., Rhodes B., Chad L., et al. Association of LY9 in UK and Canadian SLE families. Genes Immun 2008, 9:93-102. CaNIOS GenES Investigators.
22. Ferreiro-Neira I., Calaza M., Alonso-Perez E., Marchini M., Scorza R., Sebastiani G.D., Blanco F.J., Rego I., Pullmann R., Pullmann R., et al. Opposed independent effects and epistasis in the complex association of IRF5 to SLE. Genes Immun 2007, 8:429-438.
23. Hellquist A., Zucchelli M., Lindgren C.M., Saarialho-Kere U., Järvinen T.M., Koskenmies S., Julkunen H., Onkamo P., Skoog T., Panelius J., et al. Evidence for genetic association and interaction between the TYK2 and IRF5 genes in systemic lupus erythematosus. J Rheumatol 2009, 36:1631-1638.
24. Hitomi Y., Tsuchiya N., Kawasaki A., Ohashi J., Suzuki T., Kyogoku C., Fukazawa T., Bejrachandra S., Siriboonrit U., Chandanayingyong D., et al. CD72 polymorphisms associated with alternative splicing modify susceptibility to human systemic lupus erythematosus through epistatic interaction with FCGR2B. Hum Mol Genet 2004, 13:2907-2917.
25. Brown E.E., Edberg J.C., Kimberly R.P. Fc receptor genes and the systemic lupus erythematosus diathesis. Autoimmunity 2007, 40:567-581.
26. Gray-McGuire C., Moser K.L., Gaffney P.M., Kelly J., Yu H., Olson J.M., Jedrey C.M., Jacobs K.B., Kimberly R.P., Neas B.R., et al. Genome scan of human systemic lupus erythematosus by regression modeling: evidence of linkage and epistasis at 4p16-15.2. Am J Hum Genet 2000, 67:1460-1469.
27. Gaffney P.M., Langefeld C.D., Graham R.R., Ortmann W.A., Williams A.H., Rodine P.R., Moser K.L., Behrens T.W. Fine-mapping chromosome 20 in 230 systemic lupus erythematosus sib pair and multiplex families: evidence for genetic epistasis with chromosome 16q12. Am J Hum Genet 2006, 78:747-758.
28. Parham P. MHC class I molecules and kirs in human history, health and survival. Nat Rev Immunol 2005, 5:201-214.
29. Lawlor D.A., Ward F.E., Ennis P.D., Jackson A.P., Parham P. HLA-A and B polymorphisms predate the divergence of humans and chimpanzees. Nature 1988, 335:268-271.
30. McConnell T.J., Talbot W.S., McIndoe R.A., Wakeland E.K. The origin of MHC class II gene polymorphism within the genus Mus. Nature 1988, 332:651-654.
31. Morel L. Genetics of SLE: evidence from mouse models. Nat Rev Rheumatol 2010, 6:348-357.
32. von Boehmer H., Melchers F. Checkpoints in lymphocyte development and autoimmune disease. Nat Immunol 2010, 11:14-20.
33. Mathis D., Benoist C. Levees of immunological tolerance. Nat Immunol 2010, 11:3-6.
34. Li Q.Z., Zhou J., Wandstrat A.E., Carr-Johnson F., Branch V., Karp D.R., Mohan C., Wakeland E.K., Olsen N.J. Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes. Clin Exp Immunol 2007, 147:60-70.
35. Wandstrat A.E., Carr-Johnson F., Branch V., Gray H., Fairhurst A.M., Reimold A., Karp D., Wakeland E.K., Olsen N.J. Autoantibody profiling to identify individuals at risk for systemic lupus erythematosus. J Autoimmun 2006, 27:153-160.
36. Heinlen L.D., McClain M.T., Merrill J., Akbarali Y.W., Edgerton C.C., Harley J.B., James J.A. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum 2007, 56:2344-2351.
37. Shmerling R.H. Autoantibodies in systemic lupus erythematosus-there before you know it. N Engl J Med 2003, 349:1499-1500.
38. Nichols K.E., Ma C.S., Cannons J.L., Schwartzberg P.L., Tangye S.G. Molecular and cellular pathogenesis of X-linked lymphoproliferative disease. Immunol Rev 2005, 203:180-199.
39. Latour S., Roncagalli R., Chen R., Bakinowski M., Shi X., Schwartzberg P.L., Davidson D., Veillette A. Binding of SAP SH2 domain to FynT SH3 domain reveals a novel mechanism of receptor signalling in immune regulation. Nat Cell Biol 2003, 5:149-154.
40. Chan B., Lanyi A., Song H.K., Griesbach J., Simarro-Grande M., Poy F., Howie D., Sumegi J., Terhorst C., Eck M.J. SAP couples Fyn to SLAM immune receptors. Nat Cell Biol 2003, 5:155-160.
41. Roncagalli R., Taylor J.E., Zhang S., Shi X., Chen R., Cruz-Munoz M.E., Yin L., Latour S., Veillette A. Negative regulation of natural killer cell function by EAT-2, a SAP-related adaptor. Nat Immunol 2005, 6:1002-1010.
42. Snow A.L., Marsh R.A., Krummey S.M., Roehrs P., Young L.R., Zhang K., van Hoff J., Dhar D., Nichols K.E., Filipovich A.H., et al. Restimulation-induced apoptosis of T cells is impaired in patients with X-linked lymphoproliferative disease caused by SAP deficiency. J Clin Invest 2009, 119:2976-2989.
43. Zhong M.-C., Veillette A. Control of T lymphocyte signaling by Ly108, a signaling lymphocytic activation molecule family receptor implicated in autoimmunity. J Biol Chem 2008, 283:19255-19264.
44. Latour S., Gish G., Helgason C.D., Humphries R.K., Pawson T., Veillette A. Regulation of SLAM-mediated signal transduction by SAP, the X-linked lymphoproliferative gene product. Nat Immunol 2001, 2:681-690.
45. Sobel E.S., Mohan C., Morel L., Schiffenbauer J., Wakeland E.K. Genetic dissection of SLE pathogenesis: adoptive transfer of Sle1 mediates the loss of tolerance by bone marrow-derived B cells. J Immunol 1999, 162:2415-2421.
46. Sobel E.S., Satoh M., Chen Y., Wakeland E.K., Morel L. The major murine systemic lupus erythematosus susceptibility locus Sle1 results in abnormal functions of both B and T cells. J Immunol 2002, 169:2694-2700.
47. Graham D.B., Bell M.P., McCausland M.M., Huntoon C.J., van Deursen J., Faubion W.A., Crotty S., McKean D.J. Ly9 (CD229)-deficient mice exhibit T cell defects yet do not share several phenotypic characteristics associated with SLAM- and SAP-deficient mice. J Immunol 2006, 176:291-300.
48. Romero X., Zapater N., Calvo M., Kalko S.G., de la Fuente M.A., Tovar V., Ockeloen C., Pizcueta P., Engel P. CD229 (Ly9) lymphocyte cell surface receptor interacts homophilically through its N-terminal domain and relocalizes to the immunological synapse. J Immunol 2005, 174:7033-7042.
49. Crotty S., Kersh E.N., Cannons J., Schwartzberg P.L., Ahmed R. SAP is required for generating long-term humoral immunity. Nature 2003, 421:282-287.
50. Cannons J.L., Qi H., Lu K.T., Dutta M., Gomez-Rodriguez J., Cheng J., Wakeland E.K., Germain R.N., Schwartzberg P.L. Optimal germinal center responses require a multistage T Cell: B cell adhesion process involving integrins, SLAM-associated protein, and CD84. Immunity 2010, 32:253-265.
51. Qi H., Cannons J.L., Klauschen F., Schwartzberg P.L., Germain R.N. SAP-controlled T-B cell interactions underlie germinal centre formation. Nature 2008, 455:764-769.
52. Bottino C., Falco M., Parolini S., Marcenaro E., Augugliaro R., Sivori S., Landi E., Biassoni R., Notarangelo L.D., Moretta L., Moretta L. NTB-A [correction of GNTB-A], a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative disease. J Exp Med 2001, 194:235-246.
53. Stark S., Watzl C. 2B4 (CD244), NTB-A and CRACC (CS1) stimulate cytotoxicity but no proliferation in human NK cells. Int Immunol 2006, 18:241-247.
54. Garni-Wagner B., Purohit A., Mathew P.A., Bennett M., Kumar V. A novel function-associated molecule related to non-MHC-restricted cytotoxicity mediated by activated natural killer cells and T cells. J Immunol 1993, 151:60-70.
55. Mathew P., Garni-Wagner B.A., Land K., Takashima A., Stoneman E., Bennett M., Kumar V. Cloning and characterization of the 2B4 gene encoding a molecule associated with non-MHC-restricted killing mediated by activated natural killer cells and T cells. J Immunol 1993, 151:5328-5337.
56. Valiante N.M., Trinchieri G. Identification of a novel signal transduction surface molecule on human cytotoxic lymphocytes. J Exp Med 1993, 178:1397-1406.
57. Lee K.M., McNerney M.E., Stepp S.E., Mathew P.A., Schatzle J.D., Bennett M., Kumar V. 2B4 acts as a non-major histocompatibility complex binding inhibitory receptor on mouse natural killer cells. J Exp Med 2004, 199:1245-1254.
58. Vaidya S.V., Stepp S.E., McNerney M.E., Lee J.K., Bennett M., Lee K.M., Stewart C.L., Kumar V., Mathew P.A. Targeted disruption of the 2B4 gene in mice reveals an in vivo role of 2B4 (CD244) in the rejection of B16 melanoma cells. J Immunol 2005, 174:800-807.
59. McNerney M.E., Guzior D., Kumar V. 2B4 (CD244)-CD48 interactions provide a novel MHC class I-independent system for NK-cell self-tolerance in mice. Blood 2005, 106:1337-1340.
60. Lee K.M., Forman J.P., McNerney M.E., Stepp S., Kuppireddi S., Guzior D., Latchman Y.E., Sayegh M.H., Yagita H., Park C.K., et al. Requirement of homotypic NK-cell interactions through 2B4(CD244)/CD48 in the generation of NK effector functions. Blood 2006, 107:3181-3188.
61. Veillette A. NK cell regulation by SLAM family receptors and SAP-related adapters. Immunol Rev 2006, 214:22-34.
62. Beaudoin L., Laloux V., Novak J., Lucas B., Lehuen A. NKT cells inhibit the onset of diabetes by impairing the development of pathogenic T cells specific for pancreatic β cells. Immunity 2002, 17:725-736.
63. Mars L., Gautron A.S., Novak J., Beaudoin L., Diana J., Liblau R.S., Lehuen A. Invariant NKT cells regulate experimental autoimmune encephalomyelitis and infiltrate the central nervous system in a CD1d-independent manner. J Immunol 2008, 181:2321-2329.
64. Bird L. Autoimmunity: NKT cells linked to immune tolerance breakdown. Nat Rev Immunol 2010, 8.
65. Griewank K., Borowski C., Rietdijk S., Wang N., Julien A., Wei D.G., Mamchak A.A., Terhorst C., Bendelac A. Homotypic interactions mediated by Slamf1 and Slamf6 receptors control NKT cell lineage development. Immunity 2007, 27:751-762.
66. Borowski C., Bendelac A. Signaling for NKT cell development: the SAP-FynT connection. J Exp Med 2005, 201:833-836.
67. Nichols K.E., Hom J., Gong S.Y., Ganguly A., Ma C.S., Cannons J.L., Tangye S.G., Schwartzberg P.L., Koretzky G.A., Stein P.L. Regulation of NKT cell development by SAP, the protein defective in XLP. Nat Med 2005, 11:340-345.
68. Pasquier B., Yin L., Fondanèche M.C., Relouzat F., Bloch-Queyrat C., Lambert N., Fischer A., de Saint-Basile G., Latour S. Defective NKT cell development in mice and humans lacking the adapter SAP, the X-linked lymphoproliferative syndrome gene product. J Exp Med 2005, 201:695-701.
69. Eberl G., Lowin-Kropf B., MacDonald H.R. Cutting edge: NKT cell development is selectively impaired in Fyn-deficient mice. J Immunol 1999, 163:4091-4094.
70. Hu T., Simmons A., Yuan J., Bender T.P., Alberola-Ila J. The transcription factor c-Myb primes CD4+ CD8+ immature thymocytes for selection into the iNKT lineage. Nat Immunol 2010, 11:435-441.